Pancreatic cancer is among the most aggressive cancer types, with survival rates being very low and current treatment being ...

Inhibiting transient receptor potential melastatin 2 (TRPM2) may mitigate injury arising from ischemic stroke. Researchers at ...

Raqualia Pharma Inc.’s Fimecs Inc. subsidiary has agreed with Astellas Pharma Inc. to add two new targets under their ongoing ...

Kedrion SpA’s investigational plasma-derived treatment for congenital aceruloplasminemia has been awarded European orphan ...

Researchers from Stanford University have reported that inhibiting the enzyme 15-hydroxyprostaglandin dehydrogenase (15-PGDH) ...

The Sept. 4, 2015, at-risk launch of Sandoz Inc.’s Zarxio as the first biosimilar to hit the U.S. market came several months ...

CSPC Pharmaceutical Group Ltd. has gained clinical trial clearance from China’s National Medical Products Administration ...

Novo Nordisk A/S’ wild card bet that its GLP-1 receptor agonist semaglutide could be used to treat Alzheimer’s disease has ...

In an effort to develop more effective estrogen receptor α (ERα) inhibitors, researchers at Nanjing University of Chinese ...

SK Biopharmaceuticals Co. Ltd. has signed a license agreement with the Wisconsin Alumni Research Foundation (WARF) to acquire ...

Myrio Therapeutics Pty Ltd. has been able to accomplish something no other company has yet been able to crack: to develop ...

Opko Health Inc. has recently presented data for their GLP-1/glucagon receptor dual agonist OPK-88006, which is in ...